Clear All
11564 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
50242-0060-10 50242-0060 Bevacizumab Avastin 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Apr 1, 2019 Jan 31, 2023 In Use
83831-0131-01 83831-0131 Pemetrexed AXTLE 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jan 1, 2025 In Use
60505-6065-00 60505-6065 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Jun 30, 2025 In Use
82143-0001-01 82143-0001 Bevacizumab Avzivi 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGFR Intravenous Jan 1, 2025 In Use
68001-0550-41 68001-0550 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sep 7, 2022 In Use
31722-0336-31 31722-0336 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Jun 14, 2024 In Use
70069-0834-01 70069-0834 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Apr 15, 2025 In Use
50742-0340-01 50742-0340 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 24, 2022 In Use
70121-1754-07 70121-1754 Bevacizumab-maly ALYMSYS 100.0 mg/4mL Immunotherapy Monoclonal Antibody VEGF Intravenous Apr 15, 2022 In Use
68001-0543-41 68001-0543 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous Sep 1, 2022 In Use
68001-0504-54 68001-0504 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Jun 11, 2021 In Use
51991-0797-98 51991-0797 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Subcutaneous Aug 7, 2017 Jan 31, 2024 No Longer Used
43817-0906-01 43817-0906 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Subcutaneous May 6, 2019 In Use
43598-0143-62 43598-0143 Azacitidine Azacitidine 100.0 mg/50mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Apr 20, 2022 Jun 30, 2025 In Use
55513-0954-01 55513-0954 Panitumumab Vectibix 100.0 mg/5mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct 10, 2006 In Use
00069-0152-02 00069-0152 Cytarabine Cytarabine 100.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Dec 14, 2011 Dec 31, 2017 No Longer Used
57894-0505-20 57894-0505 Daratumumab Darzalex IV 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Oct 15, 2021 In Use
00703-4434-81 00703-4434 Irinotecan Hydrochloride Irinotecan Hydrochloride 100.0 mg/5mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Jul 1, 2015 Jun 30, 2019 No Longer Used
00088-1206-32 00088-1206 Dolasetron mesylate Anzemet 100.0 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sep 11, 1997 Sep 30, 2017 No Longer Used
50742-0402-05 50742-0402 Irinotecan Hydrochloride Irinotecan Hydrochloride 100.0 mg/5mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Jun 5, 2017 In Use
57894-0505-05 57894-0505 Daratumumab Darzalex IV 100.0 mg/5mL Immunotherapy Monoclonal Antibody CD38 Intravenous Oct 15, 2021 In Use
00703-4434-11 00703-4434 Irinotecan Hydrochloride Irinotecan Hydrochloride 100.0 mg/5mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Feb 28, 2008 Mar 31, 2019 No Longer Used
67457-0455-52 67457-0455 Cytarabine Cytarabine 100.0 mg/5mL Chemotherapy Antimetabolite Pyrimidine Analog Intrathecal, Intravenous, Subcutaneous Dec 14, 2011 Oct 31, 2022 No Longer Used
47335-0953-40 47335-0953 Irinotecan Hydrochloride Irinotecan Hydrochloride 100.0 mg/5mL Chemotherapy Topoisomerase I Inhibitor Camptothecin Analogs Intravenous Apr 21, 2008 Jan 24, 2017 No Longer Used
65597-0406-01 65597-0406 fam-trastuzumab deruxtecan-nxki Enhertu 100.0 mg/5mL Immunotherapy Drug Antibody Conjugate Topoisomerase I Inhibitor Intravenous Dec 20, 2019 In Use

Found 11564 results — Export these results